Dynavax Technologies EBITDA 2010-2022 | DVAX
Dynavax Technologies ebitda from 2010 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Dynavax Technologies Annual EBITDA
(Millions of US $) |
| 2021 |
$142 |
| 2020 |
$-59 |
| 2019 |
$-115 |
| 2018 |
$-140 |
| 2017 |
$-92 |
| 2016 |
$-108 |
| 2015 |
$-103 |
| 2014 |
$-89 |
| 2013 |
$-64 |
| 2012 |
$-65 |
| 2011 |
$-45 |
| 2010 |
$-45 |
| 2009 |
$-12 |
Dynavax Technologies Quarterly EBITDA
(Millions of US $) |
| 2022-03-31 |
$32 |
| 2021-12-31 |
$82 |
| 2021-09-30 |
$18 |
| 2021-06-30 |
$11 |
| 2021-03-31 |
$31 |
| 2020-12-31 |
$-10 |
| 2020-09-30 |
$-12 |
| 2020-06-30 |
$-21 |
| 2020-03-31 |
$-15 |
| 2019-12-31 |
$-24 |
| 2019-09-30 |
$-23 |
| 2019-06-30 |
$-35 |
| 2019-03-31 |
$-33 |
| 2018-12-31 |
$-35 |
| 2018-09-30 |
$-35 |
| 2018-06-30 |
$-36 |
| 2018-03-31 |
$-35 |
| 2017-12-31 |
$-26 |
| 2017-09-30 |
$-22 |
| 2017-06-30 |
$-19 |
| 2017-03-31 |
$-25 |
| 2016-12-31 |
$-19 |
| 2016-09-30 |
$-34 |
| 2016-06-30 |
$-29 |
| 2016-03-31 |
$-27 |
| 2015-12-31 |
$-26 |
| 2015-09-30 |
$-28 |
| 2015-06-30 |
$-23 |
| 2015-03-31 |
$-26 |
| 2014-12-31 |
$-22 |
| 2014-09-30 |
$-30 |
| 2014-06-30 |
$-24 |
| 2014-03-31 |
$-13 |
| 2013-12-31 |
$-12 |
| 2013-09-30 |
$-15 |
| 2013-06-30 |
$-16 |
| 2013-03-31 |
$-20 |
| 2012-12-31 |
$-19 |
| 2012-09-30 |
$-16 |
| 2012-06-30 |
$-14 |
| 2012-03-31 |
$-15 |
| 2011-12-31 |
$-4 |
| 2011-09-30 |
$-14 |
| 2011-06-30 |
$-9 |
| 2011-03-31 |
$-17 |
| 2010-12-31 |
$-15 |
| 2010-09-30 |
$-6 |
| 2010-06-30 |
$-16 |
| 2010-03-31 |
$-8 |
| 2009-12-31 |
$-11 |
| 2009-09-30 |
$-10 |
| 2009-06-30 |
$4 |
| 2009-03-31 |
$5 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.425B |
$0.439B |
|
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
|
